KRAS and melanoma: Melanoma patients with tumours harbouring KRAS mutations or amplifications represented in the SCKM-TCGA dataset were also associated with worse overall survival compared to KRAS wild-type melanomas (HR 2.59, 95% CI 1.21–5.55, p = 0.015, n = 352, univariate Cox regression), although this did not meet the threshold for statistical significance after correction of clinical covariates likely due to the limited sample size (HR 2.04, 95% CI 0.88–4.75, p = 0.098, n = 322, multivariate corrected Cox proportional hazards regression, Supplementary Fig. 5 and Supplementary Table 2).